Bernstein Assigns Bristol-Myers Squibb Company (BMY) a Hold Rating

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best undervalued stocks to buy under $50. Bristol-Myers Squibb Company (NYSE:BMY) was assigned a Hold rating by Bernstein analyst Courtney Breen on November 3, who maintained the price target at $58.

Bristol-Myers Squibb Company (NYSE:BMY) announced strong Q3 results on October 30, with both revenue and EPS exceeding expectations, supported by pipeline advancements, growth portfolio momentum, and strategic business development.

Growth portfolio revenues rose 18% to $6.9 billion compared to the prior year period, driven primarily by the company’s immuno-oncology (IO) portfolio, Reblozyl, Camzyos and Breyanzi. However, revenues of the Legacy Portfolio dropped 12% to $5.4 billion, because of expected continued generic impact across the rest of the Legacy Portfolio more than offsetting the increased demand for Eliquis. GAAP EPS for the quarter was $1.08 and non-GAAP EPS was $1.63.

Bristol-Myers Squibb Company (NYSE:BMY) also raised its full-year 2025 non-GAAP revenue guidance to an approximately $47.5 billion to $48.0 billion range from the previous range of around $46.5 billion to $47.5 billion, with the update taking into account the continued solid performance of the company’s Growth Portfolio.

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. Its medicines fall into various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.